Increased SOX2 expression in less differentiated breast carcinomas and their lymph node metastases

Histopathology

Volumn 64, Issue 4, 2014, Pages 494-503

  Huang, Yu Hua ^a   Luo, Ming Hua ^b   Ni, Yun Bi ^c   Tsang, Julia Y S ^c   Chan, Siu Ki ^d   Lui, Philip C W ^e   Yu, Alex M C ^e   Tan, Puay Hoon ^f   Tse, Gary M ^c  

^a THE FIRST AFFILIATED HOSPITAL OF SHENZHEN UNIVERSITY   (China)

^b PEKING UNIVERSITY SHENZHEN HOSPITAL   (China)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d KWONG WAH HOSPITAL   (Hong Kong)

^e Union Hospital   (Hong Kong)

^f SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

Breast cancer; Cancer stem cell; Immunohistochemistry; SOX2

Indexed keywords

BREAST CANCER; CANCER STEM CELL; IMMUNOHISTOCHEMISTRY; SOX2;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CELL DIFFERENTIATION; COHORT STUDIES; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASTIC STEM CELLS; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SOXB1 TRANSCRIPTION FACTORS;

EID: 84895067522     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12257     Document Type: Article

References (32)

1. Ferri AL, Cavallaro M, Braida D et al. SOX2 deficiency causes neurodegeneration and impaired neurogenesis in the adult mouse brain. Development 2004; 131; 3805-3819.
2. Kamachi Y, Uchikawa M, Kondoh H. Pairing SOX off: with partners in the regulation of embryonic development. Trends Genet. 2000; 16; 182-187.
3. Graham V, Khudyakov J, Ellis P, Pevny L. SOX2 functions to maintain neural progenitor identity. Neuron 2003; 39; 749-765.
4. Takahashi K, Tanabe K, Ohnuki M et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131; 861-872.
5. Yu J, Vodyanik MA, Smuga-Otto K et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007; 318; 1917-1920.
6. Maier S, Wilbertz T, Braun M et al. SOX2 amplification is a common event in squamous cell carcinomas of different organ sites. Hum. Pathol. 2011; 42; 1078-1088.
7. Neumann J, Bahr F, Horst D et al. SOX2 expression correlates with lymph-node metastases and distant spread in right-sided colon cancer. BMC Cancer 2011; 11; 518.
8. Singh S, Trevino J, Bora-Singhal N et al. EGFR/SRC/AKT signaling modulates SOX2 expression and self-renewal of stem-like side-population cells in non-small cell lung cancer. Mol. Cancer 2012; 11; 73.
9. Chen Y, Shi L, Zhang L et al. The molecular mechanism governing the oncogenic potential of SOX2 in breast cancer. J. Biol. Chem. 2008; 283; 17969-17978.
10. Rodriguez-Pinilla SM, Sarrio D, Moreno-Bueno G et al. SOX2: a possible driver of the basal-like phenotype in sporadic breast cancer. Mod. Pathol. 2007; 20; 474-481.
11. Lengerke C, Fehm T, Kurth R et al. Expression of the embryonic stem cell marker SOX2 in early-stage breast carcinoma. BMC Cancer 2011; 11; 42.
12. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies [remark]. Breast Cancer Res. Treat. 2006; 100; 229-235.
13. Lakhani SR, Ellis IO, Schnitee SJ, Tan PH, van de Vijver MJ eds. World Health Organization classification of tumors of the breast. Lyon: IARC Press, 2012.
14. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19; 403-410.
15. Tsang JY, Lai MW, Wong KH et al. Alphabeta-crystallin is a useful marker for triple negative and basal breast cancers. Histopathology 2012; 61; 378-386.
16. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ. Strategies for subtypes - dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann. Oncol. 2011; 22; 1736-1747.
17. Nielsen TO, Hsu FD, Jensen K et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin. Cancer Res. 2004; 10; 5367-5374.
18. Ben-Porath I, Thomson MW, Carey VJ et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat. Genet. 2008; 40; 499-507.
19. Simoes BM, Piva M, Iriondo O et al. Effects of estrogen on the proportion of stem cells in the breast. Breast Cancer Res. Treat. 2011; 129; 23-35.
20. Wu F, Zhang J, Wang P et al. Identification of two novel phenotypically distinct breast cancer cell subsets based on SOX2 transcription activity. Cell. Signal. 2012; 24; 1989-1998.
21. Leis O, Eguiara A, Lopez-Arribillaga E et al. SOX2 expression in breast tumours and activation in breast cancer stem cells. Oncogene 2012; 31; 1354-1365.
22. Episkopou V. SOX2 functions in adult neural stem cells. Trends Neurosci. 2005; 28; 219-221.
23. Sholl LM, Long KB, Hornick JL. SOX2 expression in pulmonary non-small cell and neuroendocrine carcinomas. Appl. Immunohistochem. Mol. Morphol. 2010; 18; 55-61.
24. Gontan C, de Munck A, Vermeij M, Grosveld F, Tibboel D, Rottier R. SOX2 is important for two crucial processes in lung development: branching morphogenesis and epithelial cell differentiation. Dev. Biol. 2008; 317; 296-309.
25. Wei B, Ding T, Xing Y et al. Invasive neuroendocrine carcinoma of the breast: a distinctive subtype of aggressive mammary carcinoma. Cancer 2010; 116; 4463-4473.
26. Zhang Y, Toy KA, Kleer CG. Metaplastic breast carcinomas are enriched in markers of tumor-initiating cells and epithelial to mesenchymal transition. Mod. Pathol. 2012; 25; 178-184.
27. Walters S, Maringe C, Butler J et al. Breast cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK, 2000-2007: a population-based study. Br. J. Cancer 2013; 108; 1195-1208.
28. Tsang JY, Huang YH, Luo MH et al. Cancer stem cell markers are associated with adverse biomarker profiles and molecular subtypes of breast cancer. Breast Cancer Res. Treat. 2012; 136; 407-417.
29. Tanei T, Morimoto K, Shimazu K et al. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin. Cancer Res. 2009; 15; 4234-4241.
30. Mihatsch J, Toulany M, Bareiss PM et al. Selection of radioresistant tumor cells and presence of ALDH1 activity in vitro. Radiother. Oncol. 2011; 99; 300-306.
31. Abraham BK, Fritz P, McClellan M, Hauptvogel P, Athelogou M, Brauch H. Prevalence of CD44 + /CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin. Cancer Res. 2005; 11; 1154-1159.
32. Guiu S, Michiels S, Andre F et al. Molecular subclasses of breast cancer: how do we define them? The Impakt 2012 working group statement. Ann. Oncol. 2012; 23; 2997-3006.